ACADIA PHARMACEUTICALS INC
At today's price, ACADIA PHARMACEUTICALS INC (ACAD) is priced for today's economics sustained for ~10.2 years. boothcheck doesn't publish a fair value or a price target; it shows what the price assumes, so you can judge whether that bar is too high. Built from SEC EDGAR filings.
- Acadia is a two-drug commercial biopharma: NUPLAZID for Parkinson's disease psychosis (about 63% of revenue) and DAYBUE for Rett syndrome (about 37%). Q1 2026 total revenue was $268 million, and the company reaffirmed full-year guidance of $1.22 billion to $1.28 billion. - The valuation is mixed in an interesting way. Several methods land above the $21.60 price (the relative valuation near $28, residual income near $36), while the price itself implies fairly demanding multi-year growth. The as
Is ACAD overvalued? See what's priced in →
326 institutional managers reported holding ACAD in 13F filings for the quarter ended 2026-03-31. 38 opened new positions that quarter. Held by BlackRock, Vanguard Group, State Street, among others. On the short side, 11.8M shares were sold short as of the 2026-06-15 count, about 7% of shares outstanding (11.3 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
ACAD's share count grew 2.1% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
No open-market insider buys on file at ACAD over the trailing three years. Absence is a fact about the company, not a signal. 19 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
ACAD's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-08-04 | -6.0% | -20.3% |
| 2023-11-04 | +5.0% | +26.0% |
| 2024-02-29 | -8.3% | -26.5% |
| 2024-05-10 | -11.8% | +16.5% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
ACAD's latest 8-K filings: 2026-05-29 (items 5.02, 5.07, 9.01); 2026-05-06 (items 2.02, 9.01); 2026-05-01 (items 5.02, 7.01, 9.01); 2026-03-05 (items 5.02); 2026-02-25 (items 2.02, 9.01).
Item codes are the SEC's own classification of what each report discloses. Nothing here is investment advice.
Last analyzed: June 27, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.